Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$18.92 - $81.86
Next Earnings Date
Jul 22 2025 (Estimate)
Next Earnings Date
Jul 22 2025 (Est.)
Latest price
Market Cap | $2.88B |
EV | $2.03B |
Shares Outstanding | 114.27M |
Beta | 0.83 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $90.61 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -12.50% |
Operating Cash Flow | -22.70% |
Free Cash Flow | -22.70% |
Revenue | - |
EPS | -44.10% |
Operating Cash Flow | -62.20% |
Free Cash Flow | -58.80% |
Gross Margin 2025E | 0.00% |
Net Profit Margin 2025E | -13759.68% |
ROE 2025E | -24.37% |
ROCE 2024 | -17.90% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Viking Therapeutics, Inc.
VKTX
Sector
Healthcare
Industry
Biotechnology
CEO
Lian, Brian
Employees
36
Website
www.vikingtherapeutics.comIPO Date
2015-04-28
Headquarters
9920 Pacific Heights Boulevard, Suite 350, San Diego, California, 92121, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved